What is the catalog number for AG-825?

The catalog number for AG-825 is HY-15844.

What sizes are available for AG-825?

AG-825 is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does AG-825 come in?

AG-825 is available in 6 different pack sizes.

AG-825 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures AG-825?

AG-825 is manufactured by QuantiMol.

What is the estimated delivery time for AG-825?

Estimated delivery time for AG-825 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for AG-825?

The safety data sheet for AG-825 is available here: http://file.medchemexpress.com/batch_PDF/HY-15844/AG-825-SDS-MedChemExpress.pdf.

AG-825

AG-825 is a selective, ATP-competitive, tyrosine phosphorylation ErbB2 inhibitor with an IC50 of 0.35 μM. AG825 significantly accelerates Apoptosis of human neutrophils. AG-825 increases β1AR density. AAG-825 has anticancer and anti-inflammatory activities. AAG-825 can be used in cardiovascular disease research[1][2][3][4][5][6][7].

Product Specifications

CAS Number

149092-50-2

Product Name Alternative

Tyrphostin AG-825

UNSPSC

12352005

Target

Adrenergic Receptor; Apoptosis; EGFR

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; JAK/STAT Signaling; Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ag-825.html

Concentration

10mM

Purity

98.02

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N)/C(C#N)=C/C1=CC(OC)=C(O)C(CSC2=NC3=CC=CC=C3S2)=C1

Molecular Formula

C19H15N3O3S2

Molecular Weight

397.47

References & Citations

[1]Wolfson E, et al. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Cell Death Dis. 2018 Jan 19;9 (2) :47.|[2]He H, et al. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 2001 May-Jun;7 (3) :191-202.|[3]Ling J, et al. Identifying key genes, pathways and screening therapeutic agents for manganese-induced Alzheimer disease using bioinformatics analysis. Medicine (Baltimore) . 2018 Jun;97 (22) :e10775.|[4]Rahman A, et al. Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation. Elife. 2019 Oct 15;8. pii: e50990.|[5]Gazit A, et al. Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36 (23) :3556-64.|[6]Piven YA, et al. Novel O-acylated (E) -3-aryl-6,7-dihydrobenzisoxazol-4 (5H) -one oximes targeting HSP90-HER2 axis in breast cancer cells. Bioorg Med Chem. 2022 Jan 1;53:116521.|[7]Gupta MK, et al. Anthracycline Cardiotoxicity Is Associated With Elevated β1-Adrenergic Receptor Density. J Am Heart Assoc. 2022 Feb 15;11 (4) :e023457.